Lymphoma Experience

CONGRESS | #EHA2026 | PRESENTATION Thomas Chatzikonstantinou presents on an international ERIC study evaluating outcomes with venetoclax-based treatment after prior BTKi therapy in patients with CLL (N = 624; BTKi stopped for CLL progression, n = 330; BTKi stopped for non-progression, n = 294). At venetoclax start, 45% received monotherapy, 37% received venetoclax + rituximab, 13% received venetoclax + obinutuzumab, and 6% received other combinations. After a median follow-up of 24 months, median TTNTD and OS in the total cohort were 33 months and 46 months, respectively. Patients stopping BTKi for progression had shorter TTNTD (28 vs 40 months; p < 0.0001) and OS (41 vs 63 months; p < 0.0001) vs those stopping for non-progression reasons. In multivariable analysis of the total cohort, non-progression as the reason for BTKi discontinuation was associated with longer TTNTD (HR, 0.68; p = 0.015) and OS (HR, 0.62; p = 0.009), while venetoclax + obinutuzumab was associated with longer TTNTD (HR, 0.46; p = 0.049) and OS (HR, 0.36; p = 0.047) vs venetoclax monotherapy. Male sex was associated with longer TTNTD (HR, 0.73; p = 0.037), while TP53 disruption was associated with shorter TTNTD (HR, 1.41; p = 0.041) and older age was associated with shorter OS (HR, 1.02; p = 0.016). Follow our live feed for more updates: loom.ly/ilKkUIM Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #lymphoma #lymsm #MedicalCongress @INAB_Institute @CERTHellas @Ericllorg